
LIST OF FIGURES AND TABLES

LIST OF FIGURES AND TABLES

CHAPTER 1: INTRODUCTION

Figure 1. 1: Anatomical division of human brain in sagittal view.....	1
Figure 1. 2: Anatomical differences in brain: Human (top) and rat (bottom).....	3
Figure 1. 3: Representation of blood brain barrier (BBB) and molecular trafficking.....	5
Figure 1. 4: Receptor mediated transcytosis of insulin across endothelial cells of blood brain barrier.....	8
Figure 1. 5: Distribution of insulin receptor (INSR) in brain.	9
Figure 1. 6: Insulin signaling pathway.....	11
Figure 1. 7: Role of insulin in brain cells.....	12
Figure 1. 8: Physiological effects of brain insulin signaling on liver, white adipose tissue, skeletal muscle and pancreas.	16
Figure 1. 9: Hypothalamic neural pathway regulated by insulin and leptin for stimulation of appetite.....	17
Figure 1. 10: Impact of insulin signaling at neuronal synapses.	18
Figure 1. 11: Molecular mechanisms of brain insulin resistance.....	20
Figure 1. 12: Prenatal disposition to brain insulin resistance	22
Figure 1. 13: Association between diabetes, hyperinsulinemia and Alzheimer’s disease.	24
Figure 1. 14: Intranasal delivery routes of drugs.	27

Table 1. 1 Function of different brain regions.	1
Table 1. 2 LMajor types of brain cells, their specific markers, key features and function.....	4

CHAPTER 2: AIMS AND OBJECTIVES

Figure 2. 1 Schematic representation of the hypothesis	30
--	----

CHAPTER 3: MATERIALS AND METHODS

Figure 3. 1 Experimental setup for tail suspension test.	32
Figure 3. 2 Hindlimb prints of rats used to calculate Sciatic function index (SFI).....	33
Figure 3. 3 Experimental setup for grip assessment test.....	34
Figure 3. 4 Dimensions used in the set-up for balance beam test.	34
Figure 3. 5 Dimensions for open field test.....	35
Figure 3. 6 Dimensions of pool used for Morris water maze test.	35
Figure 3. 7 pGeneClip hygromycin vector design.	35

Table 3. 1 List of antibodies.	44
Table 3. 2 List of primers used for gene expression studies.	45

CHAPTER 4: REGIONAL AND NEUROBEHAVIORAL STUDY OF BRAIN INSULIN RESISTANCE IN DIABETIC RAT MODEL

Figure 4. 1 Plan of work for the in vivo assessment of brain insulin resistance and its outcome in dexamethasone induced diabetic rat model.	50
Figure 4. 2 Assessment of bodyweight (in grams) (A), food intake (in grams/24 hours) (B), water intake (in ml/24 hours) (C), and oral glucose tolerance (D) in dexamethasone (dexa) treated rats and control rats	51
Figure 4. 3 Haematoxylin and eosin staining in different brain regions.....	53
Figure 4. 4 Immunoblotting of insulin signaling proteins in brain.	54
Figure 4. 5 Confocal photomicrographs showing immunostaining of brain sections.....	56
Figure 4. 6 Neurobehaviour assessment performed in dexamethasone treated (Dexa) rats versus control rats.	58
Figure 4. 7 Assessment of candidate players modulating hippocampal neural stem cell.	60
Figure 4. 8 Assessment of hippocampal astrocytic components.	61
Figure 4. 9 Neurotransmitter estimation - Glutamate (A), and GABA (B) from the hippocampus of control and dexamethasone (dexa) treated rats.....	61
Figure 4. 10 Analysis of neuropeptides' gene expression levels.	62
Figure 4. 11 Neurotransmitter estimation - Glutamate (A), GABA (B), and Dopamine (C) from the hypothalamus of control and dexamethasone (dexa) treated rats.	63
Figure 4. 12 Immunoblotting for hypothalamic nutrient sensors.....	64
Figure 4. 13 Assessment of hypothalamus astrocytic components.	64
Figure 4. 14 Plan of work for assessment of maternal insulin resistance on fetal hypothalamic appetite regulatory circuit.	65
Figure 4. 15 Gain in body weight in Control and Dexamethasone (dexa) dams during gestation.	66
Figure 4. 16 Haematoxylin and eosin staining in hypothalamus of pups born to control and dexamethasone (dexa) treated dams at postnatal day 0	68
Figure 4. 17 Immunoblotting of candidate hypothalamic proteins in male pups born to control and dexamethasone (dexa) treated rats.	69
Figure 4. 18 Immunoblotting of candidate hypothalamic proteins in female pups born to control and dexamethasone (dexa) treated rats.	70
Figure 4. 19 Analysis of neuropeptides' gene expression - Agrp (A), Npy (B), Pomc (C), Mc4r (D), Cart (E), and Crh (F) in hypothalamus of male pups at postnatal day 0	71
Figure 4. 20 Analysis of neuropeptides' gene expression-Agrp (A), Npy (B), Pomc (C), Mc4r (D), Cart (E), and Crh (F) levels in hypothalamus of female pups at postnatal day 0.....	71
Figure 4. 21 Summary of "Regional and neurobehavioral study of brain insulin resistance in glucocorticoid induced diabetic rat model".	81

Table 4. 1: Biochemical parameters of dexamethasone treated rats (Dexa) as compared to control rats.....	52
Table 4. 2 Absolute wet weight of different regions of rat brain.....	52
Table 4. 3 Pupil Dilation Test, Corneal Reflex Test, and Gait Analysis Test performed in control and dexamethasone treated (Dexa) rats.	59
Table 4. 4: Gait analysis in control and dexamethasone treated rats (Dexa) rats.	59
Table 4. 5 Open field test in dexamethasone (dexa) treated rats versus control.	59

Table 4. 6 FIRI values showing the development of insulin resistance in the dexamethasone treated (dexa) female rats after completion of dosing period.	66
Table 4. 7 Litter size and mortality of delivered pups in control and dexamethasone (dexa) treated rats.....	67
Table 4. 8 Estimation of glucose and insulin level from serum pooled from pups delivered to control and dexamethasone (dexa) treated rats at postnatal day 0 (PND0).	67
Table 4. 9: Summary of results of male and female pups as compared to respective controls.....	72

CHAPTER 5: INSULIN RESISTANCE AND GLUCOCORTICOID ON METABOLISM OF ASTROCYTES

Figure 5. 1 Astrocyte Neuron Lactate Shuttle (ANLS).	83
Figure 5. 2 Plan of work for Insr gene silencing in primary rat astrocytes.....	86
Figure 5. 3 Characterization of astrocytes by immunocytochemistry	86
Figure 5. 4 Flow cytometric analysis of astrocytes.....	87
Figure 5. 5 Insulin receptor silencing was confirmed by immunoblotting of INSR β	88
Figure 5. 6 A: Phase contrast imaging demonstrated that autophagic vacuoles (as shown by black arrows) were prominent in INSR KD astrocytes as compared to control cells. B: Immunostaining for GFAP expression in INSR KD astrocytes as compared to control cells.....	88
Figure 5. 7 MTT assay demonstrated 50% reduction in cell survival in insulin receptor knockdown (INSR KD) astrocyte as compared to transfected control (control) cells.....	88
Figure 5. 8 Cell cycle analysis by flow cytometry post transfection.	89
Figure 5. 9 A: Immunoblotting of GLUT1 and Glycogen levels in INSR KD astrocytes as compared to transfected control cells	89
Figure 5. 10 Analysis of astrocytic components of ANLS post glutamate challenge.....	90
Figure 5. 11 Plan of work for the elucidation of impact of dexamethasone on insulin signaling and function of astrocytes.	92
Figure 5. 12 MTT assay for assessment of cell survival.....	92
Figure 5. 13 Cell cycle analysis by flow cytometry in control (A), dexamethasone treated (B), insulin treated (C), insulin induced dexamethasone treated (D), RU486 and dexamethasone treated (E), and insulin induced dexamethasone +RU486 treated (F) astrocytes.	93
Figure 5. 14 Immunoblotting of candidate insulin signaling in various groups post treatment.....	94
Figure 5. 15 Representative images of immunostaining for GFAP in astrocytes post treatment	95
Figure 5. 16 GLUT1 protein expression and Glycogen levels estimated in various groups post treatment	96
Figure 5. 17 Analysis of astrocytic components of ANLS post glutamate challenge.....	97
Figure 5. 18 Summary of “The role of insulin resistance and glucocorticoid on metabolism of astrocyte”.	104

CHAPTER 6: INSULIN RESISTANCE AND GLUCOCORTICOID ON THE FATE OF NSCS

Figure 6. 1 Expression of candidate cellular markers during NSC differentiation.....	106
Figure 6. 2 Plan of work for dose dependent effect of insulin on NSC fate.	108
Figure 6. 3 Phase contrast image of formation of neurosphere and characterization of NSCs.....	109
Figure 6. 4 NSCs were differentiated into different types of neural cells.	110
Figure 6. 5 MTT assay with NSCs were incubated in different concentration of insulin.....	111

Figure 6. 6 Morphometric analysis of neurosphere formed upon incubation with different concentration of insulin for 6 days.	111
Figure 6. 7 Immunoblotting of candidate insulin signaling proteins and brain cell markers in NSCs differentiated in varying concentration of insulin.	112
Figure 6. 8 Plan of work for <i>Insr</i> gene silencing in NSC for determination of impact of insulin signaling on NSC fate.	113
Figure 6. 9 Confirmation of <i>Insr</i> gene silencing post transfection in NSCs.	113
Figure 6. 10 MTT and Neurosphere size assessment post transfection in control and INSR KD NSCs.	114
Figure 6. 11 Cell cycle analysis by flow cytometry in NSCs in <i>Insr</i> KD condition (B) as compared to transfected control cells (A).	114
Figure 6. 12 Taqman Real time gene analysis of signature markers for NSC maintenance after <i>Insr</i> gene silencing.	115
Figure 6. 13 Taqman Real time gene analysis of candidate differentiation markers for neurons (A), astrocytes (B) and oligodendrocytes (C) along with metabolic genes (D) after <i>Insr</i> gene silencing.	116
Figure 6. 14 Plan of work for assessment of impact of dexamethasone on insulin signaling and differentiation in NSC.	117
Figure 6. 15 Cell survival as demonstrated by MTT assay after treatment. Mean \pm SD of n=3 for all the groups.	117
Figure 6. 16 Cell cycle analysis by flow cytometry in control (A), dexamethasone treated (B), insulin treated (C), insulin induced dexamethasone treated (D), RU486 and dexamethasone treated (E), and insulin induced dexamethasone +RU486 treated (F) NSCs.	118
Figure 6. 17 Immunoblotting of candidate insulin signaling proteins after treatment period.	119
Figure 6. 18 Taqman Real time gene analysis of candidate differentiation markers for neurons (A), astrocytes (B) and oligodendrocytes (C) after the treatment period.	120
Figure 6. 19 Summary of “The role of insulin resistance and glucocorticoid on the fate of NSCs”.	126

CHAPTER 7: SUMMARY AND CONCLUSION

Figure 7. 1 Summary of “Cellular and molecular aspects of insulin resistance in brain”.	132
--	-----